[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352305-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352305-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dual-targeting-of-cd155-augments-the-antitumor-efficacy-of-ror1-car-t-cells-in-ovarian-cancer","Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer","","Exploring novel therapeutic targets for ovarian cancer, this study addresses limited CAR-T use in OC caused by insufficient target molecules and an immunosuppressive tumor microenvironment. ROR1 is widely expressed in tumors but barely in normal tissues, while CD155 (PVR) is studied as an immune-regulatory molecule. The work tests whether single-target ROR1-CAR-T is effective and whether CD155 is a viable target, then evaluates whether combined CD155/ROR1 targeting enhances CAR-T function in OC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dual-targeting-of-cd155-augments-the-antitumor-efficacy-of-ror1-car-t-cells-in-ovarian-cancer/352305/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dual-targeting-of-cd155-augments-the-antitumor-efficacy-of-ror1-car-t-cells-in-ovarian-cancer/352305.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is CAR-T therapy challenging in ovarian cancer?","Question",{"text":63,"@type":64},"Current CAR-T application in OC is limited by the lack of appropriate target molecules and the complex immunosuppressive tumor microenvironment (TME).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the two objectives of the study?",{"text":68,"@type":64},"The primary objective was to assess the potential efficacy of single-target ROR1-CAR-T in OC. The secondary objective was to evaluate the feasibility of CD155 as an immunotherapy target and determine whether combined CD155 targeting enhances ROR1-CAR-T function in OC.",{"name":70,"@type":61,"acceptedAnswer":71},"How did bispecific targeting of CD155 and ROR1 affect CAR-T performance?",{"text":72,"@type":64},"Bispecific CAR-T with dual targeting showed superior cytotoxicity versus single-target ROR1-CAR-T or CD155-CAR-T, attenuated tonic signaling, and delayed CAR-T cell exhaustion.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352305,1790197930,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Cancer Immunology, Immunotherapy (2026) 75:44  \n[https://doi.org/10.1007/s00262-025-04283-x](https://doi.org/10.1007/s00262-025-04283-x)  \nDual targeting of CD155 augments the antitumor efficacy of ROR1‑CAR‑T cells in ovarian cancer  \nYingjun Ye1 · Tingwei Liu1 · Chao Cheng2 · Huajing Wang2 · Jiacheng Shen1 · Xiaowen He2 · Shaohua Xu1  \nReceived: 26 August 2025 / Accepted: 19 December 2025 © The Author(s) 2025  \nAbstract  \nBackground Exploring novel therapeutic targets and developing targeted therapies constitute an urgent clinical need for improving the prognosis of ovarian cancer (OC), particularly among patients with advanced stages. Currently, chimeric antigen receptor T (CAR-T) cell therapy has been demonstrated to have a remarkable therapeutic effect in hematological malignancies, while its application remains limited in OC due to the absence of appropriate target molecules and the complex immunosuppressive tumor microenvironment (TME). Poliovirus receptor (PVR, CD155) has been the subject of extensive research in the field of regulatory molecules within the immune microenvironment. However, there has been a paucity of research investigating its role in OC. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is barely expressed in normal tissues but widely expressed in tumor tissues, making it a promising target for CAR-T therapy. Nevertheless, the potential effectiveness of CAR-T cell targeting ROR1 in OC remains unknown. Therefore, the purpose of this study is twofold: The primary objective of this study is to investigate the potential efficacy of single-target ROR1-CAR-T cells on OC. The secondary objective is to examine the feasibility of CD155 as an immunotherapy target for OC and to determine whether combined targeting of CD155 can enhance the function of ROR1-CAR-T cells in OC.  \nMethod ROR1 and CD155 expression were detected via flow cytometry analysis. In vitro experiments were conducted to explore the regulatory effect of CD155 on OC proliferation, invasion, angiogenesis, and T cell function. ROR1-CAR, CD155-CAR, and ROR1/CD155 bispecific CAR constructs were designed and synthesized. Then, they were introduced into T cells using lentiviral particles to generate CAR-T cells. We subsequently validated the synergistic effects of CD155 in ROR1/ CD155 bispecific CAR-T cells based on cytotoxic efficacy, activation, exhaustion, and differentiation status.  \nResults ROR1-CAR-T cells exhibited tumoricidal activity in OC, but elevated tonic signaling was observed, resulting in rapid depletion. CD155 constitutes an ideal therapeutic target in OC: firstly, ubiquitous CD155 expression in OC cell lines. Secondly, CD155 promotes tumor proliferation, migration, and angiogenesis in OC cell lines, acting as an oncogenic driver. Thirdly, CD155 impairs T cell function and accelerates their depletion, contributing to an immunosuppressive TME. The bispecific CAR-T combined targeting CD155 and ROR1 demonstrated superior cytotoxicity compared to single-target ROR1-CAR-T or CD155-CAR-T. Co-targeting CD155 significantly attenuated tonic signaling and delayed CAR-T cell exhaustion. Conclusion CD155 emerges as a promising therapeutic target for CAR-T therapy in OC. The bispecific CAR-T construct that co-targets CD155 and ROR1 demonstrates superior and durable tumoricidal activity, offering new perspectives on OC targeted therapy.  \nKeywords Ovarian cancer · ROR1 · CD155 · Bispecific CAR-T  \nAbbreviations GZMB Granzyme B; PD-1: Programmed cell  \nCAR-T Chimeric antigen receptor T cell death 1  \nCD155(PVR) Poliovirus receptor IFN-γ Interferon gamma  \nIL-2 Interleukin-2  \nKM Kaplan–Meier  \n   LAG-3 Lymphocyte-activation gene 3  \nYingjun Ye, Tingwei Liu, and Chao Cheng have contributed equally NK Natural killer  \nto this work. OC Ovarian cancer  \n OS Overall survival  \nExtended author information available on the last page of the article  \nPBS Phosphate-buffered saline  \nROR1 Receptor tyrosine kinase-like orphan  \nreceptor 1  \nTCGA The Canc","cbCaiqyH2qabP1cn","https://ap.wps.com/l/cbCaiqyH2qabP1cn","pdf",1840805,17,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why is CAR-T therapy challenging in ovarian cancer?\",\"answer\":\"Current CAR-T application in OC is limited by the lack of appropriate target molecules and the complex immunosuppressive tumor microenvironment (TME).\"},{\"question\":\"What were the two objectives of the study?\",\"answer\":\"The primary objective was to assess the potential efficacy of single-target ROR1-CAR-T in OC. The secondary objective was to evaluate the feasibility of CD155 as an immunotherapy target and determine whether combined CD155 targeting enhances ROR1-CAR-T function in OC.\"},{\"question\":\"How did bispecific targeting of CD155 and ROR1 affect CAR-T performance?\",\"answer\":\"Bispecific CAR-T with dual targeting showed superior cytotoxicity versus single-target ROR1-CAR-T or CD155-CAR-T, attenuated tonic signaling, and delayed CAR-T cell exhaustion.\"}]","Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer | PDF",1790098841,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c0625116028b389c47b316bf990e182.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/127904ae793eb0580579c66d67991d82.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebd3387685951cefc25a52eb6b164fc8.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7540e57e22740ec2709eddf07418daed.webp",980,1301]